Omiganan - Cutanea Life Sciences
Alternative Names: CLS-001; CPI-226; MBI-226; MBI-594AN; MX-226; MX-594AN; Omiganan pentachloride; Omiganan pentahydrochloride; Omiganan pentahydrochloride 1% gel; OmigardLatest Information Update: 29 Nov 2022
At a glance
- Originator MIGENIX
- Developer Cadence Pharmaceuticals; Carrus Capital Corporation; Cutanea Life Sciences
- Class Antibacterials; Antimicrobial cationic peptides
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Catheter infections
Highest Development Phases
- Phase III Rosacea
- Phase II Acne vulgaris; Atopic dermatitis; Condylomata acuminata; Seborrhoeic dermatitis; Vulvar intraepithelial neoplasia
- No development reported Dermatitis
- Discontinued Catheter infections
Most Recent Events
- 29 Nov 2022 Omiganan is still in phase-II trials for Seborrhoeic dermatitis in Netherlands (Topical) (EudraCT2017-003106-41)
- 28 Mar 2020 No recent reports of development identified for phase-I development in Dermatitis(Combination therapy, Monotherapy, In volunteers) in Netherlands (Topical, Gel)
- 05 Oct 2018 Cutanea Life Sciences plans a phase II trial for Seborrheic dermatitis (In adults, In the elderly) in Netherlands (Topical) (NCT03688971)